Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Advanced Technologies and Strategic Partnerships Accelerate Sustainable Agriculture Efforts Zero-Waste Inspired® Mission Continues to Drive ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...